RNS Number : 3360T Allergy Therapeutics PLC 15 January 2025 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company") PDMR Dealings Issue of 687,500,000 Warrants 15 January 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that, further to the Company's announcements on 16 October 2024 and 27 December 2023, it has issued certificates in respect of 687,500,000 warrants to subscribe for new ordinary shares in the Company ("Warrants"). As previously announced, pursuant to the terms of the £50 million loan facility under the facility agreement dated 6 April 2023 with SkyGem Acquistion Limited (an affiliate of ZQ Capital Management Limited) ("SkyGem") and Southern Fox Investments Limited ("Southern Fox"), as amended from time to time, ("the Amended Loan Facility") the Company agreed to issue 25 Warrants for every £1 drawn under the Amended Loan Facility at an exercise price of 4 pence per Warrant and exercisable on or prior to 15 October 2030. The Company confirms that is has now issued certificates in respect of 457,937,500 Warrants to SkyGem and 229,562,500 Warrants to Southern Fox in accordance with the terms of the Amended Loan Facility. In addition to these Warrants, each of Sky Gem and Southern Fox hold 16,666,666 Warrants with an exercise price of 30 pence per Warrant and exercisable until 28 February 2028. For further information, please contact: Allergy Therapeutics Manuel Llobet, Chief Executive Officer Shaun Furlong, Chief Financial Officer +44 (0)1903 845 820 Cavendish Capital Markets Limited (Nominated Adviser and Broker) Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale Nigel Birks - Life Science Specialist Sales Tamar Cranford Smith - Sales +44 (0)20 7220 0500 ICR Healthcare Mary-Jane Elliott / David Daley / Davide Salvi +44 (0)20 3709 5700 allergytherapeutics@icrhealthcare.com Notes for editors: About Allergy Therapeutics Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com. Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA") This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END DSHDBGDBBBBDGUS